Business and Finance

Discerning how and where products are discounted is an expensive headache for manufacturers

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Quad-C investment will enable future acquisitions

Canada's Rexall chain, plus Biologics, Inc, and Vantage Oncology

New healthcare proposals re-open talk of drug importation

Global drug-wholesaler group plans future educational and developmental work

Outsourced services can provide significant financial and risk-avoidance benefits

The rise in product volume is more than matched by the rise of regulatory constraints

Looking at the essential value of well-managed supply chains

IMS Health/Ego Zender survey of CIOs finds short tenures and evolving skill sets

HDMA seeks to encourage more outreach to business partners and government

'Average Manufacturer Price' is now a mostly settled matter

Deal value soared above $300 billion in 2015, but will the dealmaking sustain Big Pharma companies?

Construction index shows a steady level of North American activity

'Innovation' is the recurring theme

HDMA's 2015-16 Factbook updates member financial, operational performance

European experience to date indicates a changing perspective on biosimilar pricing

Model N/Highpoint survey points to better integration of pricing and contract data

Company has 18 products in its US pipeline